Verrica Pharmaceuticals Inc. - 8-K Filing
Verrica Pharmaceuticals reported Q1 2026 revenue of $5.0 million, including U.S. YCANTH net product revenue of $4.3 million (up 16.2% quarter-over-quarter and 25.4% year-over-year). The company also noted a record 15,302 dispensed applicator units for YCANTH in Q1 2026, up 12.1% sequentially and 51.3% year-over-year. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $VRCA